MARKET

SPPI

SPPI

Spectrum Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.850
+0.070
+1.46%
Opening 15:27 12/04 EST
OPEN
4.790
PREV CLOSE
4.780
HIGH
4.900
LOW
4.780
VOLUME
822.86K
TURNOVER
--
52 WEEK HIGH
10.57
52 WEEK LOW
1.742
MARKET CAP
707.72M
P/E (TTM)
-3.5158
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Spectrum Pharma Highlights 3 Poster Presentations At Upcoming San Antonio Breast Cancer Symposium
Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that three posters highlighting its drug development pipeline would be presented at
Benzinga · 8h ago
Spectrum Pharmaceuticals Announces Three Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
Spectrum Pharmaceuticals Announces Three Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
Business Wire · 8h ago
Will Spectrum Pharmaceuticals (NASDAQ:SPPI) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 1d ago
SmarTrend Watching for Potential Pullback in Shares of Spectrum Pharmac After 1.74% Gain
Spectrum Pharmac (NASDAQ:SPPI) traded in a range yesterday that spanned from a low of $4.32 to a high of $4.46. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $4.33 on volume of 528,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Comtex SmarTrend(R) · 11/23 17:50
FDA delays decision on Bristol Myers cancer therapy due to COVID-19 travel curbs
Reuters · 11/16 22:34
Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conferences:
BusinessWire · 11/09 09:00
Recap: Spectrum Pharmaceuticals Q3 Earnings
Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) decreased 1.36% in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share fell 22.73% over the past year to ($0.27), which beat the estimate of ($0.35).Revenue of $0 unchanged by 0.00% from the same period last year, which missed the estimate of $50,000.Guidance Spectrum Pharmaceuticals hasn't issued any earnings guidance for the time being.Spectrum Pharmaceuticals hasn't issued any revenue guidance for the time being.Details Of The Call Date: Nov 04, 2020View more earnings on SPPITime: 04:30 PMET Webcast URL: https://edge.media-server.com/mmc/p/48qdptsbPrice Action 52-week high: $10.57Company's 52-week low was at $1.74Price action over last quarter: down 4.62%Company Profile Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. As an oncology products manufacturer, it develops drugs to combat various kinds of tumors. The SPI-2012 is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN addresses immediate intravesical instillation and post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Its other products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 4, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/04 21:25
Spectrum Pharmaceuticals EPS misses by $0.02
Spectrum Pharmaceuticals (SPPI): Q3 Non-GAAP EPS of -$0.27; GAAP EPS of -$0.37 misses by $0.02.The company ended the quarter with cash, cash equivalents, and marketable securities of $198.3 million.Press Release
Seekingalpha · 11/04 21:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SPPI. Analyze the recent business situations of Spectrum Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SPPI stock price target is 10.80 with a high estimate of 15.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 257
Institutional Holdings: 97.71M
% Owned: 66.96%
Shares Outstanding: 145.92M
TypeInstitutionsShares
Increased
77
13.23M
New
46
11.02M
Decreased
26
3.90M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.52%
Pharmaceuticals & Medical Research
+1.44%
Key Executives
Chairman/Independent Director
William Ashton
President/Chief Executive Officer/Director
Joseph Turgeon
Chief Financial Officer/Executive Vice President
Kurt Gustafson
Chief Operating Officer/Executive Vice President
Thomas Riga
Executive Vice President
Francois Lebel
Senior Vice President/Secretary
Keith McGahan
Senior Vice President
Lyndah Dreiling
Independent Director
Elizabeth Czerepak
Independent Director
Seth Fischer
Independent Director
Jeffrey Vacirca
Independent Director
Dolatrai Vyas
Independent Director
Bernice Welles
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
12/10/2012
Dividend USD 0.15
12/18/2012
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SPPI
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company operates through developing and commercializing oncology and hematology drug products segment. It focuses on developing ROLONTIS and POZIOTINIB. ROLONTIS is being investigated for the treatment of chemotherapy-induced neutropenia. POZIOTINIB is an oral pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR, HER) Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Spectrum Pharmaceuticals, Inc. stock information, including NASDAQ:SPPI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPPI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SPPI stock methods without spending real money on the virtual paper trading platform.